Safety and Efficacy of SCT200 in Patients With Advanced Esophageal Squamous Cell Carcinoma

Condition:   Esophageal Squamous Cell Carcinoma
Intervention:   Drug: recombinant anti-EGFR monoclonal antibody
Sponsors:   Sinocelltech Ltd.;   Tianjin Medical University Cancer Institute and Hospital
Recruiting

http://bit.ly/2HJLHi5